NCT04381377 is a Phase 2, PHASE3 clinical trial of azoximer bromide in Infections, Coronavirus, sponsored by NPO Petrovax.

Who is sponsoring NCT04381377?

NCT04381377 is sponsored by NPO Petrovax.

What drugs are being tested in NCT04381377?

Interventions in NCT04381377: azoximer bromide, Placebo.

What condition does NCT04381377 study?

NCT04381377 studies Infections, Coronavirus.

Is NCT04381377 still recruiting?

NCT04381377 is currently completed. Last updated 23 August 2024.

Last reviewed 2024-08-23 · How we verify

NCT04381377

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19

Completed Phase 2, PHASE3 Last updated 23 August 2024

What this trial tests

Phase 2, PHASE3 trial testing azoximer bromide in Infections, Coronavirus in 394 participants. Completed in 23 April 2021.

Timeline

28 April 2020

Primary endpoint
3 March 2021

23 April 2021

Quick facts

Lead sponsor	NPO Petrovax
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	394
Start date	28 April 2020
Primary completion	3 March 2021
Estimated completion	23 April 2021
Sites	14 locations across Slovakia, Russia

Drugs / interventions tested

azoximer bromide — full drug profile →
Placebo

Conditions studied

Infections, Coronavirus — all drugs for Infections, Coronavirus →

Sponsor

NPO Petrovax — full company profile →

Who can join

Adults 18 to 85, any sex, with Infections, Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to demonstrate the superiority of Polyoxidonium®, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). This is a multicentre prospective, randomized, double-blind, placebo-controlled, parallel-group phase IIb\\IIIa clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other NPO Petrovax trials

Trials by the same sponsor.

NCT06834100 — Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug · Phase 3 · recruiting
NCT06568718 — Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyper · NA · completed
NCT06385821 — A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus · Phase 3 · completed
NCT05975879 — A Study of the Feasibility of Using the Dietary Supplement "ARTNEO" in Patients With Osteoathritis · NA · completed
NCT06383819 — Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19 · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04381377 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NPO Petrovax
Last refreshed: 23 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04381377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing